Survival of Patients with Metastatic Melanoma Treated with Ipilimumab after PD-1 Inhibitors: A Single-Center Real-World Study
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Patients
2.2. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- van Not, O.J.; van den Eertwegh, A.J.M.; Jalving, H.; Bloem, M.; Haanen, J.B.; van Rijn, R.S.; Aarts, M.J.B.; van den Berkmortel, F.W.P.J.; Blank, C.U.; Boers-Sonderen, M.J.; et al. Long-Term Survival in Patients with Advanced Melanoma. JAMA Netw. Open 2024, 7, e2426641. [Google Scholar] [CrossRef] [PubMed]
- Robert, C.; Ribas, A.; Schachter, J.; Arance, A.; Grob, J.J.; Mortier, L.; Daud, A.; Carlino, M.S.; McNeil, C.M.; Lotem, M.; et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019, 20, 1239–1251. [Google Scholar] [CrossRef]
- Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J.-J.; Rutkowski, P.; Lao, C.D.; Cowey, C.L.; Schadendorf, D.; Wagstaff, J.; Dummer, R.; et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 2019, 381, 1535–1546. [Google Scholar] [CrossRef]
- Sondak, V.K.; Smalley, K.S.M.; Kudchadkar, R.; Grippon, S.; Kirkpatrick, P. Ipilimumab. Nat. Rev. Drug Discov. 2011, 10, 411–412. [Google Scholar] [CrossRef] [PubMed]
- Hodi, F.S.; O’Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C.; et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363, 711–723. [Google Scholar] [CrossRef]
- Robert, C.; Thomas, L.; Bondarenko, I.; O’Day, S.; Weber, J.; Garbe, C.; Lebbe, C.; Baurain, J.-F.; Testori, A.; Grob, J.-J.; et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364, 2517–2526. [Google Scholar] [CrossRef]
- Long, G.V.; Robert, C.; Blank, C.U.; Ribas, A.; Mortier, L.; Schachter, J.; Middleton, M.R.; Neyns, B.; Sznol, M.; Zhou, H.; et al. Outcomes in patients treated with ipilimumab after pembrolizumab in KEYNOTE-006. Soc. Melanoma Res. Congr. 2017, 72, S128–S129. [Google Scholar] [CrossRef]
- Zimmer, L.; Apuri, S.; Eroglu, Z.; Kottschade, L.A.; Forschner, A.; Gutzmer, R.; Schlaak, M.; Heinzerling, L.; Krackhardt, A.M.; Loquai, C.; et al. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur. J. Cancer 2017, 75, 47–55. [Google Scholar] [CrossRef]
- Pires da Silva, I.; Ahmed, T.; Reijers, I.L.M.; Weppler, A.M.; Betof Warner, A.; Patrinely, J.R.; Serra-Bellver, P.; Allayous, C.; Mangana, J.; Nguyen, K.; et al. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: A multicentre, retrospective, cohort study. Lancet Oncol. 2021, 22, 836–847. [Google Scholar] [CrossRef]
- Friedman, C.F.; Spencer, C.; Cabanski, C.R.; Panageas, K.S.; Wells, D.K.; Ribas, A.; Tawbi, H.; Tsai, K.; Postow, M.; Shoushtari, A.; et al. Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: Clinical outcomes and translational biomarker analyses. J. Immunother. Cancer 2022, 10, e003853. [Google Scholar] [CrossRef]
- VanderWalde, A.; Bellasea, S.L.; Kendra, K.L.; Khushalani, N.I.; Campbell, K.M.; Scumpia, P.O.; Kuklinski, L.F.; Collichio, F.; Sosman, J.A.; Ikeguchi, A.; et al. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: A randomized phase 2 trial. Nat. Med. 2023, 29, 2278–2285. [Google Scholar] [CrossRef] [PubMed]
- Devitt, B.; Liu, W.; Salemi, R.; Wolfe, R.; Kelly, J.; Tzen, C.Y.; Dobrovic, A.; Mcarthur, G. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res. 2011, 24, 666–672. [Google Scholar] [CrossRef]
- Akbani, R.; Akdemir, K.C.; Aksoy, B.A.; Albert, M.; Ally, A.; Amin, S.B.; Arachchi, H.; Arora, A.; Auman, J.T.; Ayala, B.; et al. Genomic Classification of Cutaneous Melanoma. Cell 2015, 161, 1681–1696. [Google Scholar] [CrossRef] [PubMed]
- Hocker, T.; Tsao, H. Ultraviolet radiation and melanoma: A systematic review and analysis of reported sequence variants. Hum. Mutat. 2007, 28, 578–588. [Google Scholar] [CrossRef]
- Heppt, M.V.; Siepmann, T.; Engel, J.; Schubert-Fritschle, G.; Eckel, R.; Mirlach, L.; Kirchner, T.; Jung, A.; Gesierich, A.; Ruzicka, T.; et al. Prognostic significance of BRAF and NRAS mutations in melanoma: A German study from routine care. BMC Cancer 2017, 17, 536. [Google Scholar] [CrossRef]
- Adler, N.R.; Haydon, A.; McLean, C.A.; Kelly, J.W.; Mar, V.J. Metastatic pathways in patients with cutaneous melanoma. Pigment Cell Melanoma Res. 2017, 30, 13–27. [Google Scholar] [CrossRef] [PubMed]
- Zhou, L.; Wang, X.; Chi, Z.; Sheng, X.; Kong, Y.; Mao, L.; Lian, B.; Tang, B.; Yan, X.; Bai, X.; et al. Association of NRAS Mutation with Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials. Front. Immunol. 2021, 12, 691032. [Google Scholar] [CrossRef]
- Kirchberger, M.C.; Ugurel, S.; Mangana, J.; Heppt, M.V.; Eigentler, T.K.; Berking, C.; Schadendorf, D.; Schuler, G.; Dummer, R.; Heinzerling, L. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients. Eur. J. Cancer 2018, 98, 10–16. [Google Scholar] [CrossRef]
- Guida, M.; Bartolomeo, N.; Quaglino, P.; Madonna, G.; Pigozzo, J.; Di Giacomo, A.M.; Minisini, A.M.; Tucci, M.; Spagnolo, F.; Occelli, M.; et al. No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. Cancers 2021, 13, 475. [Google Scholar] [CrossRef]
- Jaeger, Z.J.; Raval, N.S.; Maverakis, N.K.A.; Chen, D.Y.; Ansstas, G.; Hardi, A.; Cornelius, L.A. Objective response to immune checkpoint inhibitor therapy in NRAS-mutant melanoma: A systematic review and meta-analysis. Front. Med. 2023, 10, 1090737. [Google Scholar] [CrossRef]
- Gershenwald, J.E.; Scolyer, R.A. Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Ann. Surg. Oncol. 2018, 25, 2105–2110. [Google Scholar] [CrossRef] [PubMed]
- Imai, H.; Kaira, K.; Minato, K. Clinical significance of post-progression survival in lung cancer. Thorac. Cancer 2017, 8, 379–386. [Google Scholar] [CrossRef] [PubMed]
- Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; Gwyther, S.; Mooney, M.; et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 2009, 45, 228–247. [Google Scholar] [CrossRef]
- Robert, C.; Karaszewska, B.; Schachter, J.; Rutkowski, P.; Mackiewicz, A.; Stroiakovski, D.; Lichinitser, M.; Dummer, R.; Grange, F.; Mortier, L.; et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 2015, 372, 30–39. [Google Scholar] [CrossRef]
- Cybulska-Stopa, B.; Rogala, P.; Czarnecka, A.M.; Ługowska, I.; Teterycz, P.; Galus, Ł.; Rajczykowski, M.; Dawidowska, A.; Piejko, K.; Suwiński, R.; et al. Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients—Real world evidence. Adv. Med. Sci. 2020, 65, 316–323. [Google Scholar] [CrossRef]
- Tagliaferri, L.; Lancellotta, V.; Fionda, B.; Mangoni, M.; Casà, C.; Di Stefani, A.; Pagliara, M.M.; D’Aviero, A.; Schinzari, G.; Chiesa, S.; et al. Immunotherapy and radiotherapy in melanoma: A multidisciplinary comprehensive review. Hum. Vaccin. Immunother. 2022, 18, 1903827. [Google Scholar] [CrossRef] [PubMed]
- Morgese, F.; Sampaolesi, C.; Torniai, M.; Conti, A.; Ranallo, N.; Giacchetti, A.; Serresi, S.; Onofri, A.; Burattini, M.; Ricotti, G.; et al. Gender Differences and Outcomes in Melanoma Patients. Oncol. Ther. 2020, 8, 103–114. [Google Scholar] [CrossRef]
- Jang, S.R.; Nikita, N.; Banks, J.; Keith, S.W.; Johnson, J.M.; Wilson, M.; Lu-Yao, G. Association between Sex and Immune Checkpoint Inhibitor Outcomes for Patients with Melanoma. JAMA Netw. Open 2021, 4, e2136823. [Google Scholar] [CrossRef]
- Kudura, K.; Basler, L.; Nussbaumer, L.; Foerster, R. Sex-Related Differences in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition. Cancers 2022, 14, 5145. [Google Scholar] [CrossRef]
- Jain, V.; Venigalla, S.; Nead, K.T.; Hwang, W.T.; Lukens, J.N.; Mitchell, T.C.; Shabason, J.E. Association of Gender with Efficacy of Immunotherapy in Metastatic Melanoma. J. Immunol. Sci. 2019, 3, 1–7. [Google Scholar] [CrossRef]
n = 44 pts a | % | |
---|---|---|
Age, y (range) | 68 | (36–90) |
Sex | ||
Female | 17 | 38 |
Male | 27 | 62 |
Primary tumor | ||
Cutaneous | 35 | 80 |
Mucosal | 4 | 9 |
Uveal | 1 | 2 |
Acral | 1 | 2 |
Unknown | 3 | 7 |
Mutations | ||
BRAF V600E | 7 | 16 |
BRAF V600K | 1 | 2 |
BRAF V600 b | 1 | 2 |
NRAS | 7 | 16 |
NRAS unknown | 3 | 7 |
No mutation | 25 | 57 |
Previous treatment | ||
anti-PD-1 | 44 | 100 |
anti-BRAF/MEK inhibitors | 9 | 20 |
Chemotherapy | 5 | 11 |
Metastatic sites, n | ||
>2 | 23 | 52 |
1–2 | 21 | 48 |
Brain metastases | ||
Yes | 4 | 9 |
No | 40 | 91 |
Brain radiotherapy | ||
Yes | 2 | 5 |
No | 42 | 95 |
All Patients (n = 44) | ||
---|---|---|
HR a (95% CI) | p | |
Sex | ||
Female | 1 | |
Male | 2.8 (0.9–9.1) | 0.089 |
Brain metastases | ||
No brain metastases | 1 | |
Brain metastases | 4.6 (1.1–19.2) | 0.037 |
Mutation status | ||
Wildtype | 1 | |
NRAS or BRAF mutation | 3.3 (1.1–9.3) | 0.027 |
ORR (%) | CR | PR | SD | PD | NA |
---|---|---|---|---|---|
BRAF mut (n = 9) | 0 | 11.1 | 0 | 88.9 | 0 |
NRAS mut (n = 7) | 14.3 | 14.3 | 0 | 71.4 | 0 |
BRAF/NRAS WT (n = 28) | 0 | 28.5 | 7.1 | 60.9 | 3.5 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Verkhovskaia, S.; Falcone, R.; Di Pietro, F.R.; Carbone, M.L.; Samela, T.; Perez, M.; Poti, G.; Morelli, M.F.; Zappalà, A.R.; Di Rocco, Z.C.; et al. Survival of Patients with Metastatic Melanoma Treated with Ipilimumab after PD-1 Inhibitors: A Single-Center Real-World Study. Cancers 2024, 16, 3397. https://doi.org/10.3390/cancers16193397
Verkhovskaia S, Falcone R, Di Pietro FR, Carbone ML, Samela T, Perez M, Poti G, Morelli MF, Zappalà AR, Di Rocco ZC, et al. Survival of Patients with Metastatic Melanoma Treated with Ipilimumab after PD-1 Inhibitors: A Single-Center Real-World Study. Cancers. 2024; 16(19):3397. https://doi.org/10.3390/cancers16193397
Chicago/Turabian StyleVerkhovskaia, Sofia, Rosa Falcone, Francesca Romana Di Pietro, Maria Luigia Carbone, Tonia Samela, Marie Perez, Giulia Poti, Maria Francesca Morelli, Albina Rita Zappalà, Zorika Christiana Di Rocco, and et al. 2024. "Survival of Patients with Metastatic Melanoma Treated with Ipilimumab after PD-1 Inhibitors: A Single-Center Real-World Study" Cancers 16, no. 19: 3397. https://doi.org/10.3390/cancers16193397